Carl M Gay - JoVE Visualize

Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Policies

Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Policies

Filters

Carl M Gay

Showing results (11-20 of 80) with videos related to

Pageof 8

Sort By:

Molecular Cell|January 20, 2023

Combining targeted DNA repair inhibition and immune-oncology approaches for enhanced tumor controlKyle Concannon, Benjamin B Morris, Carl M Gay, et al.

Journal of the National Comprehensive Cancer Network : JNCCN|November 2, 2014

Thymoma complicated by acquired amegakaryocytic thrombocytopenia and pure red cell aplasiaCarl M Gay, William N William, Sa A Wang, et al.

Frontiers in Oncology|November 8, 2021

Alternative Energy: Breaking Down the Diverse Metabolic Features of Lung CancersKasey R Cargill, William L Hasken, Carl M Gay, et al.

Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 15, 2019

PARP Inhibitors: Extending Benefit Beyond <i>BRCA</i>-Mutant CancersPatrick G Pilié, Carl M Gay, Lauren A Byers, et al.

Elife|May 4, 2019

GIPC proteins negatively modulate Plexind1 signaling during vascular developmentJorge Carretero-Ortega, Zinal Chhangawala, Shane Hunt, et al.

Translational Lung Cancer Research|January 10, 2022

SLFN11 biomarker status predicts response to lurbinectedin as a single agent and in combination with ATR inhibition in small cell lung cancerKiran Kundu, Robert J Cardnell, Bingnan Zhang, et al.

Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|December 28, 2025

The impact of targeting TRAF2 and NCK-interacting protein kinase (TNIK) on anti-tumor effect and tumor immune environment in c-MYC-high small cell lung cancerAzusa Tanimoto, Kavya Ramkumar, C Allison Stewart, et al.

Cancer|March 30, 2023

Neoadjuvant immunotherapy for advanced, resectable non-small cell lung cancer: A systematic review and meta-analysisYajing Wu, Vivek Verma, Carl M Gay, et al.

Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 24, 2025

Multidimensional Analysis of B7 Homolog 3 RNA Expression in Small Cell Lung Cancer Molecular SubtypesCarl M Gay, Taofeek K Owonikoko, Lauren A Byers, et al.

Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 28, 2018

Differential Sensitivity Analysis for Resistant Malignancies (DISARM) Identifies Common Candidate Therapies across Platinum-Resistant CancersCarl M Gay, Pan Tong, Robert J Cardnell, et al.

Pageof 8

Search research articles

Showing results (11-20 of 80) with videos related to

Sort By:

Pageof 8

Molecular Cell|January 20, 2023

Combining targeted DNA repair inhibition and immune-oncology approaches for enhanced tumor controlKyle Concannon, Benjamin B Morris, Carl M Gay, et al.

Journal of the National Comprehensive Cancer Network : JNCCN|November 2, 2014

Thymoma complicated by acquired amegakaryocytic thrombocytopenia and pure red cell aplasiaCarl M Gay, William N William, Sa A Wang, et al.

Frontiers in Oncology|November 8, 2021

Alternative Energy: Breaking Down the Diverse Metabolic Features of Lung CancersKasey R Cargill, William L Hasken, Carl M Gay, et al.

Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 15, 2019

PARP Inhibitors: Extending Benefit Beyond <i>BRCA</i>-Mutant CancersPatrick G Pilié, Carl M Gay, Lauren A Byers, et al.

Elife|May 4, 2019

GIPC proteins negatively modulate Plexind1 signaling during vascular developmentJorge Carretero-Ortega, Zinal Chhangawala, Shane Hunt, et al.

Translational Lung Cancer Research|January 10, 2022

SLFN11 biomarker status predicts response to lurbinectedin as a single agent and in combination with ATR inhibition in small cell lung cancerKiran Kundu, Robert J Cardnell, Bingnan Zhang, et al.

Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|December 28, 2025

Cancer|March 30, 2023

Neoadjuvant immunotherapy for advanced, resectable non-small cell lung cancer: A systematic review and meta-analysisYajing Wu, Vivek Verma, Carl M Gay, et al.

Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 24, 2025

Multidimensional Analysis of B7 Homolog 3 RNA Expression in Small Cell Lung Cancer Molecular SubtypesCarl M Gay, Taofeek K Owonikoko, Lauren A Byers, et al.

Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 28, 2018

Differential Sensitivity Analysis for Resistant Malignancies (DISARM) Identifies Common Candidate Therapies across Platinum-Resistant CancersCarl M Gay, Pan Tong, Robert J Cardnell, et al.

Pageof 8